Sonnet biotherapeutics announces a collaboration with roche for the clinical evaluation of son-1010 with atezolizumab in ovarian cancer

Sonnet's lead product, son-1010, to be evaluated in combination with roche's atezolizumab (tecentriq®) sonnet will sponsor the clinical study in patients with platinum-resistant ovarian cancer, scheduled to commence during the second calendar quarter of 2023, and roche will supply atezolizumab princeton, nj / accesswire / january 9, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn), a clinical-stage company developing targeted immunotherapeutic drugs, announced today a clinical collaboration agreement with roche. a clinical trial (sb221) will be conducted to assess the safety and preliminary efficacy of son-1010 (il12-fhab) in combination with roche's atezolizumab in patients with platinum-resistant ovarian cancer (proc).
SONN Ratings Summary
SONN Quant Ranking